COMMUNIQUÉS West-GlobeNewswire

-
OMass Therapeutics to Present New Preclinical Data For its Best-in-Class MC2 Program at ENDO 2025
07/07/2025 -
European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia
07/07/2025 -
VitalHub Announces Acquisition of Novari Health Inc.
07/07/2025 -
Tonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025
07/07/2025 -
BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure
07/07/2025 -
Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21
07/07/2025 -
Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia
07/07/2025 -
Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development
07/07/2025 -
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
07/07/2025 -
Boehringer Ingelheim initiates Phase II study of BI 1815368, a potential first-in-class oral treatment for diabetic macular edema
07/07/2025 -
Orchard Therapeutics Announces Last Patient Treated in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome
07/07/2025 -
CORRECTION – Dr. Anosh Ahmed Announces Major Expansion of COVID Testing Contracts Across U.S. and International Markets
07/07/2025 -
BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development
07/07/2025 -
The Joint Corp. Closes Sale of 31 Corporate Clinics in Arizona and New Mexico and Acquires Regional Developer Rights in the Northwest Region
07/07/2025 -
Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic Mastocytosis
07/07/2025 -
Yiviva Presents Phase 2b Results for YIV-906 in Combination with Sorafenib in Advanced Hepatocellular Carcinoma at ASCO and ESMO GI 2025
07/07/2025 -
Onco360 Has Been Selected as a National Specialty Pharmacy for Augtyro™ (repotrectinib)
07/07/2025 -
Quipt Home Medical Acquires Healthcare System Owned Medical Equipment Provider with $6.6 Million in Revenue, and Signs Preferred Provider Agreement Covering 20 Hospitals Across 4 States
07/07/2025 -
Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria
07/07/2025
Pages